Hao-Yu Wang
Latest contributions
Refining PCI plannings and decision-making with novel technologies
21 May 2026 – From EuroPCR 2026
This session highlights cutting-edge technologies that enhance PCI planning and decision-making. It covers the clinical populations benefiting from QFR-guided revascularisation, prognostic insights from radial wall strain in DCB-treated vessels, and advances in artificial intelligence and machine learning to assess ischemia and predict PCI outcomes, especially in...
New evidence for pharmacology for coronary artery disease
19 May 2026 – From EuroPCR 2026
This session presents the latest evidence in pharmacological management of coronary artery disease, featuring pivotal trials such as VESALIUS-CV and TARGET FIRST. It covers topics including evolocumab efficacy post-stenting, early aspirin cessation strategies, aspirin-free protocols after complex PCI in ACS, and comparative outcomes of clopidogrel versus...